Maxim lowered the firm’s price target on SeaStar Medical (ICU) to $6 from $10 and keeps a Buy rating on the shares. The firm cites the company having announced the publication of positive early post-approval clinical experience from the use of the QUELIMMUNE therapy in the peer-reviewed journal of Pediatric Nephrology, though its price target reflects SeaStar’s share dilution, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICU: